131 related articles for article (PubMed ID: 21442636)
1. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
[TBL] [Abstract][Full Text] [Related]
2. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
[TBL] [Abstract][Full Text] [Related]
3. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of pomalidomide therapy in myelofibrosis.
Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
[TBL] [Abstract][Full Text] [Related]
5. Clinical Correlates and Prognostic Significance of IL-8, sIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis.
Barabanshikova MV; Dubina IA; Lapin SV; Morozova EV; Vlasova JJ; Ivanova MO; Moiseev IS; Afanasyev BV
Oncol Res Treat; 2017; 40(10):574-578. PubMed ID: 28946149
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
8. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
[TBL] [Abstract][Full Text] [Related]
9. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
[TBL] [Abstract][Full Text] [Related]
10. Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
[No Abstract] [Full Text] [Related]
11. Pruritus in primary myelofibrosis: clinical and laboratory correlates.
Vaa BE; Wolanskyj AP; Roeker L; Pardanani A; Lasho TL; Finke CM; Tefferi A
Am J Hematol; 2012 Feb; 87(2):136-8. PubMed ID: 22081434
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.
Evereklioglu C; Er H; Türköz Y; Cekmen M
Mediators Inflamm; 2002 Apr; 11(2):87-93. PubMed ID: 12061429
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Schlenk RF; Stegelmann F; Reiter A; Jost E; Gattermann N; Hebart H; Waller C; Hochhaus A; Platzbecker U; Schafhausen P; Blau IW; Verbeek W; Heidel FH; Werner M; Kreipe H; Teleanu V; Benner A; Döhner H; Grießhammer M; Döhner K
Leukemia; 2017 Apr; 31(4):889-895. PubMed ID: 27774990
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
[No Abstract] [Full Text] [Related]
16. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
18. [Studies on the relationship between the level of cytokine and liver function in patients with clonorchiasis sinensis].
Cai LS; Xiao JY; Xin H; Zhu LX; Chen G; Zhang T; Wang GZ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):54-6. PubMed ID: 15283270
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
